BioXcel Therapeutics (BTAI) Long-Term Debt Issuances (2017 - 2022)
BioXcel Therapeutics (BTAI) posted Long-Term Debt Issuances of $30.0 million for Q3 2022, up 8186.25% on a QoQ basis from -$371000.0 in Q1 2018.
Powered by 
Analysis
BioXcel Therapeutics (BTAI) Long-Term Debt Issuances (2017 - 2022) Analysis & Trends
BioXcel Therapeutics has reported Long-Term Debt Issuances for 3 years, with the latest figure at $30.0 million in Q3 2022.
- On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $30.0 million in Q3 2022; TTM through Dec 2022 was $30.0 million, a N/A change from a year earlier, with the FY2022 full-year figure at $98.6 million, changed N/A from the prior year.
- Long-Term Debt Issuances was $30.0 million for Q3 2022 at BioXcel Therapeutics, up from -$371000.0 in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $30.0 million in Q3 2022, with the low at -$371000.0 in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | 1.32 Bn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | - |
| 10 | BioXcel Therapeutics | 2.19 Mn | 2.19 Mn | 160,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 30.00 Mn |
| Mar 31, 2018 | -371,000.00 |
| Dec 31, 2017 | 2,000.00 |
| Sep 30, 2017 | 84,000.00 |